Related Experiment Video

Updated: Mar 13, 2026

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
10:38

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Published on: December 16, 2022

2.9K

Imatinib alters cell viability but not growth factors levels in TM4 Sertoli cells

Seyyed Mohammad Reza Hashemnia1, Somayeh Atari-Hajipirloo1, Shiva Roshan-Milani1

  • 1Department of Biochemistry, Tehran University of Medical Sciences and Urmia University of Medical Sciences, Urmia and Tehran, Iran.

International Journal of Reproductive Biomedicine
|October 15, 2016
PubMed
Abstract

Insights

The anticancer drug imatinib (IM) significantly reduced Sertoli cell viability in mice. While IM increased platelet-derived growth factor (PDGF) and stem cell factor (SCF) levels, its impact on male fertility requires further investigation.

Area of Science:

  • Reproductive Biology
  • Cancer Therapeutics
  • Cell Biology

Background:

  • Imatinib (IM) is an ATP-competitive tyrosine kinase inhibitor used in cancer therapy.
  • IM targets platelet-derived growth factors (PDGFs) and stem cell factor (SCF) receptors, crucial for cancer cell proliferation.
  • PDGF and SCF also play vital roles in the development and function of normal testicular cells, including Sertoli cells.

Purpose of the Study:

  • To investigate the effects of imatinib (IM) on the viability of normal mouse Sertoli cells.
  • To assess the impact of IM on the levels of PDGF and SCF in Sertoli cells.
  • To explore the potential implications of IM treatment on male reproductive health.

Main Methods:

  • Mouse TM4 Sertoli cells were exposed to varying concentrations of IM (0-20 μM) for 2, 4, or 6 days.
  • Cell viability was quantified using the MTT assay.
  • Levels of PDGF and SCF were measured via ELISA.
  • Statistical significance was determined using One-Way ANOVA.

Main Results:

  • Imatinib (IM) treatment resulted in a statistically significant decrease in Sertoli cell viability in a dose-dependent manner (p=0.001).
  • IM exposure led to an insignificant increase in PDGF and SCF levels compared to the control group (p>0.05).

Conclusions:

  • Imatinib induces a dose-dependent reduction in Sertoli cell viability.
  • The study suggests a potential link between imatinib treatment and male fertility.
  • Further research is warranted to elucidate the specific roles of PDGF and SCF in IM-affected Sertoli cells and their contribution to fertility processes.
Keywords:
Cell viabilityImatinib mesylatePlatelet derived growth factorSertoli cellsStem cell factor

More Related Videos

Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques09:48

Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques

Published on: June 30, 2017

7.9K
Generation of 3D Tumor Spheroids for Drug Evaluation Studies10:33

Generation of 3D Tumor Spheroids for Drug Evaluation Studies

Published on: February 24, 2023

3.0K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K